Genenta Science S.p.A. (NASDAQ:GNTA – Get Free Report)’s share price was down 2% on Tuesday . The stock traded as low as $3.37 and last traded at $3.42. Approximately 3,259 shares were traded during trading, a decline of 37% from the average daily volume of 5,184 shares. The stock had previously closed at $3.49.
Genenta Science Stock Performance
The stock’s fifty day moving average is $3.65 and its 200-day moving average is $4.33.
Genenta Science Company Profile
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
Featured Stories
- Five stocks we like better than Genenta Science
- Insider Buying Explained: What Investors Need to Know
- Garmin Navigates to New Highs Driven By Wearables Trend
- How to Choose Top Rated Stocks
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- Stock Market Sectors: What Are They and How Many Are There?
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Genenta Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genenta Science and related companies with MarketBeat.com's FREE daily email newsletter.